Innoviva, Inc. is a diversified biopharmaceutical company with a royalty portfolio of respiratory assets partnered with GSK (RELVAR/BREO ELLIPTA and ANORO ELLIPTA), and a critical care and infectious disease platform (Innoviva Specialty Therapeutics) anchored by five commercial products: GIAPREZA, XACDURO, XERAVA, ZEVTERA, and NUZOLVENCE. The company also holds strategic healthcare investments including a significant stake in Armata Pharmaceuticals. Innoviva transitioned from a pure-play royalty business to a diversified biopharmaceutical company through acquisitions and licensing agreements.
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-25 | 2025-12-31 | 0001193125-26-071776 | EDGAR | 98K words |
| 2025-02-26 | 2024-12-31 | 0000950170-25-027864 | EDGAR | 103K words |
| 2024-02-29 | 2023-12-31 | 0000950170-24-023237 | EDGAR | 99K words |
| 2023-02-28 | 2022-12-31 | 0000950170-23-005168 | EDGAR | 99K words |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002169 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001104659-21-028328 | EDGAR | — |
| 2020-02-19 | 2019-12-31 | 0001104659-20-022807 | EDGAR | — |
| 2019-02-19 | 2018-12-31 | 0001047469-19-000541 | EDGAR | — |
| 2018-02-23 | 2017-12-31 | 0001047469-18-001016 | EDGAR | — |
| 2017-02-28 | 2016-12-31 | 0001047469-17-001057 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001193125-26-335235 | EDGAR | 30K words |
| 2025-11-05 | 2025-09-30 | 0001193125-25-267040 | EDGAR | 34K words |
| 2025-08-06 | 2025-06-30 | 0000950170-25-104126 | EDGAR | 32K words |
| 2025-05-07 | 2025-03-31 | 0000950170-25-065765 | EDGAR | 29K words |
| 2024-11-06 | 2024-09-30 | 0000950170-24-122375 | EDGAR | 34K words |
| 2024-07-31 | 2024-06-30 | 0000950170-24-088661 | EDGAR | 33K words |
| 2024-05-08 | 2024-03-31 | 0000950170-24-055832 | EDGAR | 30K words |
| 2023-11-01 | 2023-09-30 | 0000950170-23-057530 | EDGAR | 37K words |
| 2023-08-02 | 2023-06-30 | 0000950170-23-037296 | EDGAR | 35K words |
| 2023-05-09 | 2023-03-31 | 0000950170-23-019835 | EDGAR | 31K words |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023933 | EDGAR | — |
| 2022-07-27 | 2022-06-30 | 0000950170-22-013224 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-05 | 0001193125-26-335192 | EDGAR | 3K words |
| 2026-02-25 | 0001193125-26-071974 | EDGAR | 4K words |
| 2025-11-05 | 0001104659-25-107014 | EDGAR | 4K words |
| 2025-08-06 | 0001104659-25-074730 | EDGAR | 3K words |
| 2025-05-21 | 0001104659-25-051614 | EDGAR | 1K words |
| 2025-05-07 | 0001104659-25-045556 | EDGAR | 3K words |
| 2025-02-26 | 0001104659-25-017461 | EDGAR | 3K words |
| 2024-11-06 | 0001104659-24-114800 | EDGAR | 3K words |
| 2024-07-31 | 0001104659-24-084357 | EDGAR | 3K words |
| 2024-06-20 | 0001104659-24-073416 | EDGAR | 1K words |
353 total filings indexed. 321 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001080014 |
| Ticker | INVA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | Burlingame, CA |
| Website | https://www.inva.com |
| Listed | 2004-10-05 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/INVA (~200 tokens, structured JSON with cryptographic provenance)